Me

Patent No. 1398023

Foreign Application 5 June 1972



Date of Patent. 25 October 1972

Date of Sealing 15 October 1975

dizabeth the Second by the Grace of God of the United Kingdom of Great Britain and Northern Ireland and of Her other Realms and Territories, Queen, Head of the Commonwealth, Defender of the Faith: To all to whom these presents shall come greeting:

WHEREAS a request for the grant of a patent has been made by

Institut Toxikologii Ministerstva Zdravo-Okhranenia SSSR, a State Enterprise organised and existing under the laws of the Union of Soviet Socialist Republics, (U.S.S.R.), of l ulitsa Bekhtereva, Leningrad, Union of Soviet Socialist Republics,

for the sole use and advantage of an invention for

Process for producing 6- $\omega$ -(3'phenyl-pyrrodidyl-1')-propionylbenzo-1, 4-dioxane, its salts, and process for producing same:

AND WHEREAS We, being willing to encourage all inventions which may be for the public good, are graciously pleased to condescend to the request:

KNOW YE, THEREFORE, that We, of our especial grace, certain knowledge, and mere motion do by these presents, for Us, our heirs and successors, give and grant unto the person(s) above named and any successor(s), executor(s), administrator(s) and assign(s) (each and any of whom are hereinafter referred to as the patentee) our especial licence, full power, sole privilege, and authority, that the patentee or any agent or licensee of the patentees and no others, may subject to the conditions and provisions prescribed by any statute or order for the time being in force at all times hereafter during the term of years herein mentioned, make, use, exercise and vend the said invention within our United Kingdom of Great Britain and Northern Ireland, and the Isle of Man, and that the patentee shall have and enjoy the whole profit and advantage from time to time accruing by reason of the said invention during the term of sixteen years from the date hereunder written of these presents: AND to the end that the patentee may have and enjoy the sole use and exercise and the full benefit of the said invention, We do by these presents for Us, our heirs and successors, strictly command all our subjects whatsoever within our United Kingdom of Great Britain and Northern Ireland, and the Isle of Man, that they do not at any time during the continuance of the said term either directly or indirectly make use of or put in practice the said invention, nor in anywise imitate the same, without the written consent, licence or agreement of the patentee, on pain of incurring such penalties as may be justly inflicted on such offenders for their contempt of this our Royal Command, and of being answerable to this patentee according to law for damages thereby occasioned:

PROVIDED ALWAYS that these letters patent shall be revocable on any of the grounds from time to time by law prescribed as grounds for revoking letters patent granted by Us, and the same may be revoked and made void accordingly:

PROVIDED ALSO that nothing herein contained shall prevent the granting of licences in such manner and for such considerations as they may by law be granted: AND lastly, We do by these presents for Us, our heirs and successors, grant unto the patentee that these our letters patent shall be construed in the most beneficial sense for the advantage of the patentee.

IN WITNESS whereof We have caused these our letters to be made patent as of the twenty-fifth day of October

one thousand nine hundred and Seventy-two and to be sealed.

Gowand aming

Comptroller-General of Patents
Designs, and Trade Marks.

## NOTE

You are reminded that this patent is granted for a term beginning on the date of the filing on the complete specification (that is the date of the patent given overleaf) and ending at the expiration of 16 years from that date, subject to the payment by you or by someone on your behalf, before the expiration of the 4th and each succeeding year during the term of the patent, of the prescribed fees. All or any of these annual payments may be made in advance and a Patents Form 24 should accompany the appropriate fees.

You are warned that if the form with the fee is not lodged in the Patent Office on or before the anniversary date of the patent, the fee cannot be accepted unless application for an extension of time to a maximum of 6 months is made and paid for on Patents Form 25. Thereafter if no renewal fee is received and no extension of time is requested, the patent will cease.

No reduction of extension fees is made in the case of a patent endorsed "Licences of Right". When paying a renewal or extension fee you are advised to check the current scale of charges as these may change from time to time.

If any person becomes entitled by assignment, transmission or other operation of law to this patent, or a part interest therein, or to any interest as mortgagee or licensee or otherwise, application must be made to the Comptroller to register such title of interest (see Section 74 of the Patents Act). Particulars as to the manner of making such application may be obtained from the Patent Office.

## PROCEDURE FOR PAYMENT OF FEES

Patents fees are payable direct to the Patent Office by means of cash, money order, postal order, banker's draft or cheque. (Adhesive stamps will not be accepted in payment of fees.) The prescribed fee must be submitted together with the appropriate completed Patents Form; in addition each form or batch of forms should be accompanied by a fee sheet (FS. 1) showing details of the form(s) and the amount(s) of the fee(s). Cheques, money orders, etc., should be made payable to "The Comptroller-General, Patent Office", and crossed. Patents Forms, together with the fees and fee sheet (FS. 1) may be delivered to the Patent Office in London either by hand or by post; those sent by post should be addressed to "The Cashier, The Patent Office, 25 Southampton Buildings, London WC2A 1AY".

Blank Patents Forms and fee sheets (FS. 1) can be obtained from the Clerk of Stationery, The Patent Office, 25 Southampton Buildings, London WC2A 1AY.

## PATENT SPECIFICATION

(11) 1398 023

98023

(21) Application No. 49120/72 (22) Filed 25 Oct. 1972

(31) Convention Application No. 1788853 (32) Filed 5 June 1972 in

(33) Soviet Union (SU)

(44) Complete Specification published 18 June 1975

(51) 1NT CL<sup>2</sup> C07D 405/06 A61K 31/40//(C07D 405/06 207/08 319/20)

(52) Index at acceptance

C2C 1341 1692 213 215 220 226 22Y 246 250 251 253 25Y 28X 29X 29Y 30Y 351 355 386 43X 625 675 790 UK

(72) Inventors SERGEI GEORGIEVICH KUZNETSOV
DAVID VLADIMIROVICH IOFFE
ALEXANDR GRIGORIEVICH CHIGAREV
SERGEI SERGEEVICH KRYLOV and
NADEZHDA TIMOFEEVNA STARYKH



(71) We, INSTITUT TOXIKOLOGII MINISTERSTVA ZDRAVOOKHRANE-NIA SSSR, a State Enterprise organised and existing under the laws of the Union of Soviet Socialist Republics, (U.S.S.R.), of 1 ulitsa Bekhtereva, Leningrad, U.S.S.R., do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

The present invention relates to a process for producing 6 -  $\omega$  - (3<sup>1</sup> - phenylpyrrolidyl-1<sup>1</sup>) - propionylbenzo - 1,4 - dioxane and

15 salts thereof and the salts per se.

6 - ω - (3¹ - phenylpyrrolidyl - 1¹)-propionylbenzo - 1,4 - dioxane hydrochloride, referred to as pyrroxane, is useful as a medicinal compound. (Pyrroxane is a Trade Mark registered in the USSR).

A process is known in the art (cf. British Patent No. 1,237,158) for producing  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1) - \text{propionylbenzo} - 1,4 - \text{dioxane, comprising the con-$ 

densation of 3 - phenylpyrrolidine, 6 - acetylbenzo - 1,4 - dioxane, and formaldehyde. The product yield in this prior-art process does not exceed 59% by weight.

It is an object of the present invention 30 to provide a novel process which makes it possible to increase the product yield.


It is another object of the present invention to produce novel salts of  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1)$  - propionylbenzo - 1, 4 - dioxane.

According to the present invention there is provided a process for producing 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane, which comprises reacting 3 - phenylpyrrolidine with 6 -  $\omega$  - di-

(3<sup>1</sup> - or ) - 1, tio

methylaminopropionylbenzo - 1,4 - dioxane in the presence of an alkaline agent in an organic solvent medium. The reaction may be performed by stirring a mixture of 3 - phenylpyrrolidine,  $6 - \omega$  - dimethylaminopropionylbenzo - 1,4 - dioxane, and an alkaline agent such as sodium carbonate in a weight ratio of 1:1:2 respectively in an organic solvent medium such as dimethylformamide at ambient temperature with the removal of dimethylamine by an inert gas.  $6 - \omega$  - dimethylaminopropionylbenzo - 1,4 - dioxane may be employed for the reaction in the form of a

base or salt (hydrochloride, methyliodide). Further according to the present invention there is provided a novel salt of  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1) - \text{propionylbenzo} - 1,4 - \text{dioxane of the formula:}$ 



wherein A is a chlorine-free mineral acid or an organic acid.

These salts find use in medicinal prepara-

Such acids may be exemplified by hydrobromic acid, sulphuric acid, phosphoric acid, nitric acid, benzene or p - toluenesulphonic acid, tartaric acid, nicotinic acid, maleic acid, citric acid, salicylic acid, ascorbic acid, lac-



55

[Price 33p]

65

70

85

90

tic acid, acetic acid, formic acid, benzoic acid, succinic acid, glutaric acid and adipic acid. Such salts may be exemplified as follows; 6 - ω - (3¹ - phenylpyrrolidyl - 1¹) - pro-

6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane hydrobromide, 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane hydrogen sulphate; 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹)-propionylbenzo - 1,4 - dioxane tartrate; 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane maleate; 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane citrate; and 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane citrate; and 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,

4 - dioxane succinate.

Still further according to the present invention there is provided a process for producing said salts, comprising reacting 6 - ω - (3¹ - phenylpyrrolidyl - 1¹) - propionyl20 benzo - 1,4 - dioxane with an appropriate mineral or organic acid. The reaction may be effected by adding an acid solution in a suitable solvent to a solution of the 6 - ω - (3¹ - phenylpyrrolidyl - 1¹) - propionyl25 benzo - 1,4 - dioxane in ether.

Said salts of  $6 - \omega - (3^1 - \text{phenylpyrrolidyl-} 1^1) - \text{propionylbenzo} - 1,4 - \text{dioxane, as well}$  as pyrroxane, possess a pronounced peripheral and central adrenoblocking action (mainly on alpha - receptors). In addition, they reveal a lasting hypotensive effect and block central action of nicotine.

These salts possess the same pharmacological activity as pyrroxane. When tested on cats in 35 a dose of 0.5 to 1.0 mg per kg of bodyweight of cat, they eliminate or distort peripheral effects of catechol amines. Central adrenoblocking action of the salts is manifested at a dose of 10 to 15 mg/kg of cat. 40 LD<sub>30</sub> of the salt of the present invention ranges from 130 to 150 mg/kg of cat.

Salts of 6 - w - (3¹ - phenylpyrrolidyl-1¹) - propionylbenzo - 1,4 - dioxane may find wide application in medicine as efficient medicinal compounds for treating diseases and states associated with a pathological rise of sympathetic tone of the nervous system, primarily the central one.

For a better understanding of the present invention, specific Examples are given hereinbelow by way of embodiments.

Example 1

Into a mixture of 2.94 g (0.02 g mol) of 3 - phenylpyrrolidine, 4.70 g (0.02 g mol) of 6 -  $\omega$  - dimethylaminopropionylbenzo-1,4 - dioxane, and 4.12 g (0.04 g mol) of sodium carbonate in 40 ml of dimethylformamide a current of nitrogen is introduced with stirring. After 6 hours the resulting mass is added to 200 ml of water, extracted with ether, and the extracts are dried with  $K_2O_3$ . The desiccant is filtered off, the ether is distilled off almost until dryness (to the residue

volume of 10 ml), the residue is cooled to 0 to  $+5^{\circ}$ C, and kept at this temperature for 4 hours. The resulting precipitate is filtered off, washed on a filter with 3 ml of ether, and dried at a temperature of 40 to 50°C to give 4.75 g (70.5%) of 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1, 4 - dioxane with a melting point of 64—65°C.

Example 2

A mixture of 2.94 g (0.02 g mol) of 3 - phenylpyrrolidine, 7.55 g (0.02 g mol) of 6 -  $\omega$  - dimethylaminopropionylbenzo - 1,4 - dioxane methyl iodide and 4.12 g (0.04 g mol) of sodium carbonate in 40 ml of dimethylformamide is stirred for 6 hours, while introducing nitrogen. Further treatment is performed in accordance with the procedure described in Example 1. The yield of 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo-1,4 - dioxane is 5.2 g (76.5%); melting point, 64 to 65°C.

Example 3

To 14 ml of a 1.5% by weight solution of  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1)$  - propionylbenzo - 1,4 - dioxane in anhydrous diethyl ether a 48% by weight solution of hydrobromic acid is added to give pH of 3. The precipitate is filtered off and crystallized from acetone to yield 71% by weight of  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1)$  - propionylbenzo-1,4 - dioxane hydrobromide, melting point 142 to 144°C. Found, %: N, 3.54; Br, 18.75;  $C_{21}H_{23}NO_3HBr$ . Calculated, %: N, 3.36; Br, 19.08.

Example 4

6 - ω - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane hydrogen sulphate is produced by adding a 5% by weight solution of sulphuric acid in anhydrous diethyl ether to 14 ml of a 1.5% by weight solution of 6 - ω - (3¹ - phenylpyrrolidyl-1¹) - propionylbenzo - 1,4 - dioxane in anhydrous ether. Further treatment is effected in much the same manner as that described in Example 3. The desired product yield is 86% by weight; melting point, 71—75°C 110 (isopropanol). Found, %: N, 3.36;  $C_{21}H_{23}NO_3$  .  $H_2SO_4$ . Calculated, %: N, 3.22.

Example 5

6 -  $\omega$  -  $(3^1$  - phenylpyrrolidyl -  $1^1$ ) - 115 propionylbenzo - 1,4 - dioxane tartrate is produced in a manner similar to that described in Example 3, utilizing a saturated solution of tartaric acid in anhydrous ether. The salt is obtained having a melting point of above 50°C. Found, N, 2.70;  $C_{21}H_{23}NO_3$ .  $C_3H_4O_5$ . Calculated, %: N, 2.86.

Example 6

6 - ω - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane maleate is produced in a manner similar to that described in Example 3, utilizing a saturated solution of maleic acid in anhydrous ether. The salt yield is 79% by weight; melting point, 123 to 127°C (ethanol). Found, N, 3.17. C<sub>21</sub>H<sub>23</sub>NO<sub>3</sub> . C<sub>2</sub>H<sub>2</sub>O<sub>4</sub>. Calculated, %: N, 3.10.

Example 7

 $6 - ω - (3^1 - phenylpyrrolidyl - 1^1) - propionylbenzo - 1,4 - dioxane citrate is produced in a similar manner to that described in Example 3, utilizing a saturated solution of citric acid in anhydrous ether. The salt is produced having a melting point above <math>60^\circ C$ . Found, N, 2.86;  $C_{21}H_{23}NO_3 \cdot C_6H_8O_8$ . Calculated, %: N, 2.66.

Example 8
6 - ω - (3¹ - phenylpyrrolidyl - 1¹) - propionylbenzo - 1,4 - dioxane succinate is produced in a manner similar to that described in Example 3, utilizing a saturated
solution of succinic acid in anhydrous ether. The salt yield is 82% by weight, melting point, 87 to 90°C (ethanol). Found, %: N, 3.24; C₂¹H₂₃NO₃ . C₄H₆O₄. Calculated, %: N, 3.08.

30 WHAT WE CLAIM IS:—

1. A process for producing  $6 - \omega - (3^1 - 1)$  phenylpyrrolidyl -  $1^1$ ) - propionylbenzo - 1, 4 - dioxane comprising reacting 3 - phenylpyrrolidine with  $6 - \omega$  - dimethylaminopropionylbenzo - 1,4 - dioxane in the presence of an alkaline agent in an organic solvent medium.

2. A process as claimed in claim 1, wherein the reaction of 3 - phenylpyrrolidine, 6 - 40 - dimethylaminopropionylbenzo - 1,4 - dioxane, and the alkaline agent is conducted in the weight ratio of 1:1:2 respectively in an organic solvent medium at ambient temperature, with the removal of the resulting dimethylamine with an inert gas.

3. A process as claimed in claim 1 or 2, wherein the alkaline agent is sodium carbonate

4. A process as claimed in any one of claims 1 to 3, wherein the organic solvent is dimethylformamide.

5. A salt of  $6 - \omega - (3^1 - \text{phenylpyrrolidyl-} 1^1) - \text{propionylbenzo} - 1,4 - \text{dioxane of the formula}:$ 

$$C_6H_5$$
 $C_6H_5$ 
 $C_6H_2C$ 
 $C_6H_5$ 
 $C_6H_5$ 
 $C_6H_5$ 
 $C_6H_5$ 
 $C_6H_5$ 
 $C_6H_5$ 
 $C_6H_5$ 
 $C_6H_5$ 

wherein A is chlorine-free mineral acid or an organic acid.

6.  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1) - \text{propionylbenzo} - 1,4 - \text{dioxane hydrobromide according to claim 5.}$ 

7. 6 -  $\omega$  - (3<sup>1</sup> - phenylpyrrolidyl - 1<sup>1</sup>) - propionylbenzo - 1,4 - dioxane hydrogen sulphate according to claim 5.

8. 6 -  $\omega$  - (3<sup>1</sup> - phenylpyrrolidyl - 1<sup>1</sup>)-propionylbenzo - 1,4 - dioxane tartrate according to claim 5.

9. 6 -  $\omega$  - (3¹ - phenylpyrrolidyl - 1¹)-propionylbenzo - 1,4 - dioxane maleate according to claim 5.

10. 6 -  $\omega$  - (3<sup>1</sup> - phenylpyrrolidyl - 1<sup>1</sup>) - propionylbenzo - 1,4 - dioxane citrate according to claim 5.

11. 6 -  $\omega$  - (3<sup>1</sup> - phenylpyrrolidyl - 1<sup>1</sup>) - propionylbenzo - 1,4 - dioxane succinate according to claim 5.

12. A process for producing a salt as claimed in claim 5, comprising reacting  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1)$  - propionylbenzo - 1,4 - dioxane with an appropriate organic or mineral acid

13. A process as claimed in claim 12, wherein the organic acid is an acid selected from tartaric acid, citric acid, lactic acid, acetic acid, formic acid, nicotinic acid, maleic acid, salicylic acid, ascorbic acid, benzoic acid, succinic acid, adipic acid and benzene or p-toluenesulphonic acid.

14. A process as claimed in claim 12, wherein the mineral acid is an acid selected from hydrobromic acid, sulphuric acid, phosphoric acid, and nitric acid.

15. A process for producing  $6 - \omega - (3^1 - \beta)$  phenylpyrrolidyl -  $1^1$ ) - propionylbenzo - 1, 4 - dioxane according to claim 1, substantially as hereinbefore described and with reference to Examples 1 and 2.

16.  $6 - \omega - (3^1 - \text{phenylpyrrolidyl} - 1^1)$ -propionylbenzo - 1,4 - dioxane whatever prepared by the process claimed in any one of claims 1 to 4 and 15.

17. A process for producing a salt of 6 -  $\omega$  - (3<sup>1</sup> - phenylpyrrolidyl - 1<sup>1</sup>) - propionylbenzo - 1,4 - dioxane according to claim 12

. .

I-

75

80

85

90

95

95

100

substantially as hereinbefore described and with reference to any one of Examples 3 to 8.

18. A salt of  $6 - \omega - (3^1 - \text{phenyl-pyrrolidyl} - 1^1) - \text{propionylbenzo} - 1,4 - \text{dioxane whenever prepared by a process as claimed in any one of claims 12 to 14 and claim 17.$ 

FITZPATRICKS,
Chartered Patent Agents,
14—18 Cadogan Street,
Glasgow, G2 6QW,
and
Warwick House,
Warwick Court,
London, WC1R 5DJ.

Printed for Her Majesty's Stationery Office, by the Courier Press, Leamington Spa, 1975. Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.

Ne287

ТОРГОВО-ПРОМЫШЛЕННАЯ ПАЛАТА СССР Управление по патентованию изобретений

Начальнику отдела В. ГЛАДЫРЮ

Москва К-3, ул.Куйбышева,6

Кас.патента № 1398023 в Англии на изобретение: "Способ получения..." Заявка в СССР № 1788853/23

Ha Bam W 08IO P.46IIO or 22.03.76

Институт токсикологии МЗ СССР подтверждает получение патентной грамоты/описания № 1398023, выданной Патентным

на ашебку в названии провребения: Сидует песать 6-w- (3 phenyl - pyrrolidyl - ...)

ЗАВ. НАУЧНО-ОРГАНИЗА ЦИОННЫМ ОТДЕЛОМ, к.м.н.

(O. KBACEHKO)